Article
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Gastroenterology - 1 Dec 2011
Zeuzem Stefan, Asselah Tarik, Angus Peter, Zarski Jean-Pierre, Larrey Dominique, Müllhaupt Beat, Gane Ed, Schuchmann Marcus, Lohse Ansgar, Pol Stanislas, Bronowicki Jean-Pierre, Roberts Stuart, Arasteh Keikawus, Zoulim Fabien, Heim Markus, Stern Jerry O, Kukolj George, Nehmiz Gerhard, Haefner Carla, Boecher Wulf Otto
Abstract excerpt
BACKGROUND & AIMS: Therapeutic regimens are being developed for patients with hepatitis C virus (HCV) infection that do not include the combination of peginterferon alfa and ribavirin. We investigated the antiviral effect and safety of BI 201335 (an inhibitor of the NS3/4A protease) and BI 207127 (an inhibitor of the NS5B non-nucleoside polymerase) with ribavirin. METHODS: Thirty-two treatment-naïve patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.